Fenoprofen
 | |
| Systematic (IUPAC) name | |
|---|---|
| 2-(3-phenoxyphenyl)propanoic acid | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a681026 |
| |
| |
| Oral | |
| Pharmacokinetic data | |
| Metabolism | Major urinary metabolites are fenoprofen glucuronide and 4′-hydroxyfenoprofen glucuronide. |
| Half-life | 3 hours |
| Excretion | Renal (~90%) |
| Identifiers | |
29679-58-1  | |
| M01AE04 | |
| PubChem | CID 3342 |
| DrugBank |
DB00573 |
| ChemSpider |
3225 |
| UNII |
RA33EAC7KY |
| KEGG |
D02350 |
| ChEBI |
CHEBI:5004 |
| ChEMBL |
CHEMBL1297 |
| Chemical data | |
| Formula | C15H14O3 |
| 242.26986 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Fenoprofen is a non-steroidal anti-inflammatory drug. Fenoprofen calcium is used for symptomatic relief for rheumatoid arthritis, osteoarthritis, and mild to moderate pain. Fenoprofen is marketed in the USA as Nalfon.
Pharmacology
Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.
Contraindications
History of significantly impaired renal function; patients with known hypersensitivity to any component of the product; patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Drug interactions
- Aminoglycosides (e.g. gentamicin): Plasma aminoglycoside levels may be elevated.
- Angiotensin-converting enzyme (ACE) inhibitors: Antihypertensive effect of ACE inhibitors may be diminished.
- Anticoagulants: Coadministration may prolong prothrombin time.
- Aspirin: Fenoprofen Cl may be increased; coadministration is not recommended.
- Diuretics: Patients treated with fenoprofen may be resistant to the effects of loop diuretics and thiazides.
- Hydantoins, sulfonamides, sulfonylureas: Fenoprofen may displace these drugs from their binding site.
- Lithium: Renal Cl of lithium may be reduced and plasma levels may be elevated, which may increase the risk of lithium toxicity.
- Methotrexate: May increase methotrexate levels.
- Phenobarbital: May decrease fenoprofen t ½ . Dosage adjustments of fenoprofen may be required if phenobarbital is added or withdrawn.
- SSRIs (e.g. fluoxetine, citalopram): The risk of GI effects may be increased.
Laboratory test interactions
False elevation in free and total serum T 3 as measured by Amerlex-M kit.
Brand names
- UK - Fenopron (Typharm Limited)
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||